KRT5 and neoplasm: Our tumor analysis revealed CK5 positivity in 21.1% (4.4% weak, 2.7% moderate, 14.0% strong) and CK6 positivity in 22.8% (8.4% weak, 4.1% moderate, 10.4% strong) of tumors.